Ignyta, Inc. (OTCQB: RXDX), an oncology precision medicine biotechnology company, today announced financial results for the full year ended December 31, 2013.
“2013 was a transformational year for Ignyta, as we focused the business on oncology precision medicine, in-licensed two proprietary oral tyrosine kinase inhibitor product candidates, became a publicly-traded company through our reverse merger transaction and raised substantial capital to bolster our balance sheet,” said Jonathan Lim, M.D., Chairman and CEO of Ignyta.
Help employers find you! Check out all the jobs and post your resume.
